Targeted co-delivery of docetaxel and plumbagin via oxidative priming enhances chemoradiotherapy in non-small cell lung cancer
Xueying Bao, Huanhuan Wang, Man Li, Zhuangzhuang Zheng, Xuanzhong Wang, Jianfeng Guo, Xin Jiang · 2026
Read Targeted co-delivery of docetaxel and plumbagin via oxidative priming enhances chemoradiotherapy in non-small cell lung cancer by Xueying Bao, Huanhuan Wang, Man Li, Zhuangzhuang Zheng, Xuanzhong Wang, Jianfeng Guo, Xin Jiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13330687.txt.
Description
Xueying Bao and colleagues pair two drugs in a targeted nanoparticle to boost lung cancer chemoradiation in a 2026 study. Plumbagin, a natural redox agent, unsettles tumour chemistry and sensitises cells to docetaxel. Dose needs fell sharply in two lung cancer cell lines when the pair was used, the authors report.
A folate-guided liposome carried both drugs together to fix mismatched body handling. With radiation, harmful oxygen build-up inside cells rose well above radiation alone in those tests. In mice, radiation plus the targeted pair curbed tumours by 99 percent in the reported results, with steady weight and no clear blood, liver, or kidney harm. Low-dose gains with safety are the promise.
Catalog record
| CREATOR | Xueying Bao, Huanhuan Wang, Man Li, Zhuangzhuang Zheng, Xuanzhong Wang, Jianfeng Guo, Xin Jiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89871 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |